To determine if monocyte chemotactic and activating factor (MCAF) induces intracellular antimicrobial activity, human monocyte-derived macnophages were treated with MCAF and challenged with Toxoplasma gondii and Leishmania donouani. Pretreatment with MCAF induced macrophages to inhibit protozoa1 replication by approximately 50%. These findings suggest a potential host defense role for MCAF in the inflammatory response to intracellular pathogens.
Introduction
The chemokine, human monocyte chemotactic and activating factor (MCAF), is a pro-inflammatory cytokine expressed in many cell types including macrophages, fibroblasts, keratinocytes, and smooth muscle cells in response to inflammatory stimuli such as interleukin I (IL-l), interferon-y @N-y), tumor necrosis factor-o (TNF-a), and bacterial lipopolysaccharide [l-7] . In vitro, MCAF at nanogram concentrations is a monocyte chemoattractant which also induces superoxide anion and lysosomal enzyme release and monocyte-mediated antitumor activity [8-lo] .
In vivo, MCAF inhibits tumor growth in nude mice and protects neutropenic mice against otherwise lethal bacterial infections [11, 12] , presumably reflecting monocyte recruitment and activation. Since cytokine-induced mononuclear phagocyte acti-* Corresponding author vation is also associated with control of intracellular protozoa1 infections [ 13,141, we challenged MCAFtreated human monocyte-derived macrophages with Toxoplasma gondii or Leishmania donovani and analyzed subsequent intracellular parasite replication. 
Materials and methods

Methods for in vitro infection
Results
Under the conditions employed, both T. gondii (Table 1) and L. donouani (Table 2 ) readily parasitized unstimulated human macrophages and showed approximately 5-fold increases in intracellular replication by 18 h and 72 h, respectively. Pretreatment with 1 and 5 ng/ml of MCAF induced little or no activity against either T. gondii or L. donovani (data not shown). For T. gondii, maximal inhibition of replication was observed in cells pretreated with 10 and 100 ng/ml of MCAF resulting in 44% to 48% reduction in replication (Table 1) . Pretreatment with 1000 ng/ml did not further increase this microbistatic activity (data not shown). Results from two Table 1 Inhibition of T. gondii replication by MCAF-stimulated human macrophages additional experiments with T. gondii (not shown) demonstrated that while pretreatment of macrophages for 30 min with 100 ng/ml of MCAF had no effect, 24 h of preincubation with 100 ng/ml was as effective as 72 h (46% mean reduction in replication). Adding 100 ng/ml of MCAF after parasite challenge only, however, had no appreciable effect on T. gondii replication.
In two experiments which yielded similar results, MCAF also induced microbistatic activity in L. donouani-infected macrophages (Table 2) . Peak inhibition of L. donovuni replication (50%) was induced by 72 h of pretreatment with 100 ng/ml; pretreatment with IO-fold more MCAF did not increase this effect (Table 2 ). In one of these experiments, MCAF treatment (100 ng/ml) of macrophages for both 72 h before and after infection did not enhance the level of inhibition of replication (57%) induced by 72 h of pretreatment alone (55%).
Protective immunity against T. gondii and L. donoauni, intracellular protozoans which readily infect mononuclear phagocytes, is predominantly cellmediated [ 13,161. Cytokines including IFW-y appear to play an important role this response, presumably by activating macrophages to inhibit or kill these pathogens [ 13, . MCAF is induced by some of the same cytokines (e.g. IFN-y, TNF-a) known to be generated in response to infection with T. gondii and L. donouuni [13, 19, 21] ; thus, MCAF may also be present in the same inflammatory environment. In our study, MCAF was active in vitro at lo-100 ng/ml, a concentration similar to that which en- 
